title: [Medical termination of pregnancy at 9-14 weeks gestation. Prospective study of 105 cases in Saint-Laurent-du-Maroni (French Guyana)].
abstract: OBJECTIVE
  To demonstrate the effectiveness and safety of mifepristone 600mg with misoprostol 800 mg, for termination of pregnancy at 9-14 weeks gestation.
  
  
  METHODS
  This prospective study included 105 women at 9 to 14 weeks gestation given 800 mg of vaginal misoprostol, 2 or 3 days after a single dose of 600 mg of mifepristone for pregnancy termination. Outcomes measures included mean expulsion time, the interval between fotal and placental expulsion, adverse effects, vaginal bleeding, requirement for analgesia, and hospital stay, analyzed by parity and gestational age.
  
  
  RESULTS
  Pregnancy termination was successful in 92.4% of the patients without requirement for surgery. The mean time to expulsion was 6 hours. The fetus and placenta were expelled together in 79% of the cases. In 15% the conception products were retained in the cervical canal, and removed with a ring forceps. Additional misoprostol doses were necessary in 33% and analgesia (nalbuphine sublingually, mean dose was 10mg) in 56%. Significant bleeding was observed in 7.5%, leading to curettage in 2 patients. No statistically significant differences were found between the rate of success and term (9-12 versus 12-14) or parity.
  
  
  CONCLUSIONS
  Combining oral mifepristone and vaginal misoprostol is a successful alternative to surgical termination of pregnancy, even after 9 weeks' gestation. The use of nalbuphine for analgesia improves acceptability; sublingual administration helps avoid invasive procedures. Before 14 weeks gestation, the legal limit for termination of pregnancy in France, the choice between the surgical and medical alternatives should be left to the patient.
authors.affiliation: Service de Gynécologie-Obstétrique, Centre Hospitalier de l'Ouest Guyanais, Saint-Laurent-du-Maroni (Guyane française).
authors.forename: M
authors.initials: M
authors.lastname: Largeaud
authors.forename: W
authors.initials: W
authors.lastname: El Guindi
authors.forename: F
authors.initials: F
authors.lastname: Perotti
authors.forename: Y
authors.initials: Y
authors.lastname: Montoya
authors.forename: G
authors.initials: G
authors.lastname: Carles
authors.forename: B
authors.initials: B
authors.lastname: Seve
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced; D000029:Abortion, Legal / Q000379:methods; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007902:Length of Stay; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D009266:Nalbuphine / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011446:Prospective Studies; D012449:Safety; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D000701:Analgesics, Opioid; D016595:Misoprostol; D015735:Mifepristone; D009266:Nalbuphine